Published date: 9 January 2023

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 10 February 2023, 5pm

Contract summary

Industry

  • Pharmaceutical products - 33600000

  • Various medicinal products - 33690000

Location of contract

United Kingdom

Value of contract

£120,000,000

Procurement reference

CF-1263600D0O000000rwimUAA

Published date

9 January 2023

Closing date

10 February 2023

Closing time

5pm

Contract start date

1 April 2023

Contract end date

31 March 2024

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Yes

Description

The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England.
Anti Veg-F medicines are currently used in the treatment of:
a. neovascular (wet) age-related macular degeneration (AMD);
b. visual impairment due to diabetic macular oedema (DME/DMO);
c. visual impairment due to myopic choroidal neovascularisation (myopic CNV); and
d. visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

Period of framework: 1 April 2023 to 31 March 2024 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 24 months)
Framework Reference Number: CMD/SCM/MJP/2023/01
Atamis Reference Number: C123966

http://health.atamis.co.uk/

About the buyer

Contact name

Mary-Jo Pryor

Address

80 London Roaf
London
SE1 6LH
GB

Email

mary-jo.pryor@nhs.net